Bionomics (BNOX)
(Delayed Data from NSDQ)
$0.92 USD
-0.03 (-2.83%)
Updated Apr 23, 2024 03:58 PM ET
After-Market: $0.95 +0.03 (2.90%) 4:28 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
BNOX 0.92 -0.03(-2.83%)
Will BNOX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BNOX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BNOX
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals
Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%
BNOX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate
Bears are Losing Control Over Bionomics Limited Unsponsored ADR (BNOX), Here's Why It's a 'Buy' Now
Can Bionomics Limited Unsponsored ADR (BNOX) Climb 329% to Reach the Level Wall Street Analysts Expect?
Other News for BNOX
12 Health Care Stocks Moving In Tuesday's After-Market Session
Buy Rating Affirmed for Bionomics’ BNC210 Following Promising PTSD Study Results
Bionomics’s BNC210 Shows Promise for PTSD Treatment: A Buy Rating Analysis
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
Bionomics' BNC210 shows significant improvement in PTSD